Fasikl
Fasikl is a neuro-AI company developing the FDA-cleared Felix NeuroAI Wristband, a prescription wearable that delivers AI-driven, adaptive peripheral nerve stimulation to provide all-day tremor relief for adults with essential tremor, alongside an investigational nerve-computer interface pipeline for paralysis and chronic pain.
- Company typePrivate
- Founded2019
- HeadquartersBloomington, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Fasikl does
Fasikl, Inc. is a venture-backed neuro-AI company founded in 2019 as a spin-off from the University of Minnesota and headquartered in Bloomington, Minnesota. The company develops AI-powered therapeutic technologies that decode and modulate peripheral neural signals to treat neurological disorders, building on more than 20 years of accumulated R&D across the University of California, the National University of Singapore, and the University of Minnesota. Its flagship commercial product is the Felix NeuroAI Wristband—an FDA 510(k)-cleared (K243678, July 2025) prescription wearable that delivers adaptive, transcutaneous peripheral nerve stimulation to provide all-day tremor relief for adults with essential tremor, a condition affecting approximately 7 million Americans. The technology stack combines patented neuro-microchips capable of single-fiber resolution peripheral nerve recording with proprietary NeuroAI algorithms running on a cloud-based platform, enabling closed-loop stimulation that continuously adapts to each patient's tremor profile in real time. Fasikl also operates an investigational pipeline—Fasikl-X, MindForce NCI (FDA Breakthrough Device Designation, with TAP admission), and Epione—targeting amputee and paralysis applications including prosthetic control and chronic post-amputation pain.
The company operates a prescription-only DME business model in which healthcare providers (neurologists, movement disorder specialists, and prescribing physicians) prescribe the Felix wristband, and fulfillment, billing, and customer support are handled by its wholly-affiliated entity, Fasikl Medical Solutions (FMS). FMS bills across a diversified payer mix—Medicare, Medicaid, Medicare Advantage, commercial insurers (PPO/HMO), VA, and self-pay—and the company supports providers with documentation, coverage guidance, and on-site Provider Support Representatives. Patients access the device via a website-based reservation/waitlist system. Marketing emphasizes clinical credibility through the JAMA Neurology publication (October 2025), AAN 2025 Late-Breaking Science presentation, ATMRD 2024 Best Poster Award, named KOL endorsements, and patient testimonials. The company has raised approximately $59.8M in equity funding across four priced rounds and a Google Cloud credit grant, with a staged U.S. commercial rollout beginning in 2025 and nationwide expansion planned for 2026.
Fasikl firmographics
Firmographics- Name
- Fasikl
- Legal name
- Fasikl, Inc.
- Website
- https://fasikl.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Fasikl is a neuro-AI company developing the FDA-cleared Felix NeuroAI Wristband, a prescription wearable that delivers AI-driven, adaptive peripheral nerve stimulation to provide all-day tremor relief for adults with essential tremor, alongside an investigational nerve-computer interface pipeline for paralysis and chronic pain.
- Ownership category
- akta.pro rank
Fasikl industry classification
Industry- Product category
- AI Neuromodulation Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
- akta.pro secondary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where Fasikl is headquartered
LocationHeadquarters
- HQ city
- Bloomington
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Fasikl business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
Revenue model
- Felix NeuroAI Wristband Device Sales (Prescription DME): Fasikl generates primary revenue through sales of its FDA-cleared Felix NeuroAI Wristband as a durable medical equipment (DME) product, dispensed by prescription through healthcare providers. Distribution and billing are handled via the company's affiliated entity, Fasikl Medical Solutions (FMS). The device is covered through Medicare, Medicare Advantage, commercial insurers (PPO, HMO), VA, and self-pay/private pay channels. Revenue cycle operations include claims submission, denial management, appeals, payer enrollment, and credentialing.
- Series B Venture Capital Investment: Fasikl closed a $26.5 million Series B funding round in September 2025 to accelerate development and commercialization of next-generation AI therapeutics. This follows prior rounds including $18.3M Series A+ (September 2024), $10M Series A (March 2023), and $5M Pre-Series A (November 2021), for a cumulative total of approximately $59.8M raised. Funding supports R&D, clinical trials, and commercial preparations for Felix launch.
- Google Cloud Credits (Google for Startups Program): Fasikl received $300,000 in Google Cloud credits through the Google for Startups Cloud Program, which supports AI startup infrastructure. This reduces operating costs for cloud-based AI platform operations rather than generating direct revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | No public pricing disclosed — prescription DME with insurance billing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Fasikl product offering
Product offeringCore offering
Fasikl develops and sells AI-powered neurotechnology devices for treating neurological disorders. Its flagship product is the FDA-cleared Felix NeuroAI Wristband, a non-invasive, prescription-only wearable that delivers adaptive peripheral nerve stimulation guided by a cloud-based AI platform to provide all-day relief from essential tremor. The company also develops investigational nerve-computer interface systems (MindForce NCI, Epione, Fasikl-X) for prosthetic control and chronic post-amputation pain.
Product overview
Fasikl is a neuro-AI company developing AI-powered therapeutic technologies. The company's portfolio consists of the FDA-cleared Felix NeuroAI Wristband as its flagship product—a wearable device for essential tremor—alongside the investigational Fasikl-X Nerve-Computer Interface platform (including MindForce NCI for prosthetic control). The Felix wristband and its companion mobile app connect to Fasikl's cloud-based AI platform to deliver personalized, adaptive neuromodulation therapy. The Fasikl-X platform represents the company's next-generation research into nerve-computer interfaces for paralysis and pain management.
Differentiator
Problem solved
Functional benefit
Brands
- Felix NeuroAI Wristband: FDA-cleared AI-powered wearable wristband that delivers personalized neuromodulation therapy for essential tremor, providing all-day tremor relief through cloud-based AI collaboration with the brain
- Fasikl-X Nerve-Computer Interface
- MindForce NCI System
- Epione System
Products and services
- Felix NeuroAI Wristband FDA-cleared, non-invasive, prescription-only wearable wristband that delivers personalized, adaptive transcutaneous peripheral nerve stimulation to reduce essential tremor. Connects to Fasikl's cloud-based AI platform which continuously adjusts stimulation in real time based on neural and movement data. Indicated for adults with tremor-related functional limitations in upper limbs; can be used independently or alongside medication.
- MindForce NCI System Investigational nerve-computer interface that captures and interprets neural signals at single-fascicle resolution to enable amputees and paralyzed patients to intuitively control robotic limbs or computer devices by thinking. Also delivers targeted neuromodulation to alleviate chronic neuropathic post-amputation pain.
- Epione Chronic Pain System Investigational system that alleviates chronic, intractable post-amputation pain by recreating sensations through peripheral neurostimulation as part of Fasikl's implantable platform portfolio.
Quantifiable outcome
- Mean 6.9-point improvement in modified Activities of Daily Living (mADL) score at 90 days vs. 2.7 points for sham group (p<0.0001)
- +4 more outcomes
Companies that use Fasikl
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Fasikl technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability5 records
Feature5 records
Fasikl partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Google (Google for Startups Cloud Program)coreFasikl joined the Google for Startups Cloud Program, receiving $300,000 in Google Cloud credits along with access to Google's leading AI technology, infrastructure, and foundational models. This supports the company's cloud-based AI platform operations for its Felix NeuroAI Wristband and ongoing AI therapeutic development.
- Google Cloud PlatformcoreGoogle Cloud Platform hosts and processes Felix app data as part of Fasikl's cloud-based AI infrastructure. Google Cloud is certified under SOC 2 and ISO 27001 standards.
- Fasikl Medical Solutions (FMS)coreFMS is a wholly-affiliated entity that handles durable medical equipment fulfillment, billing to Medicare/Medicaid/commercial insurers, and customer support for patients and caregivers. Patient information is shared with FMS as a separate covered entity (or business associate) under HIPAA for treatment, payment, and healthcare operations purposes.
Scale indicators5 records
Recent moves10 records
Expansion highlights6 records
Fasikl competitors and assessment
Company assessmentDirect peers
- Cala Health: Cala Health develops the Cala Trio, a non-invasive wrist-worn TAPS (transcutaneous afferent patterned stimulation) device for essential tremor — the most direct wearable competitor to Fasikl's Felix NeuroAI Wristband, targeting the same patient population and prescribing neurologists.
- InSightec: InSightec commercializes Exablate Neuro, an MR-guided focused ultrasound system for incisionless treatment of essential tremor. Comparable as another non-pharmacological, non-DBS alternative for essential tremor, targeting the same neurology specialist prescriber base.
Broad incumbents
- Medtronic: Medtronic is the dominant incumbent in neuromodulation, offering Activa deep brain stimulation (DBS) systems for essential tremor and other movement disorders, plus a broad neurostimulation portfolio. Comparable as the established alternative Fasikl positions Felix against for non-invasive, drug-free tremor therapy.
- Abbott: Abbott's neuromodulation business (formerly St. Jude Medical) markets the Infinity DBS system for movement disorders and a broad peripheral nerve stimulation portfolio. Comparable as an established surgical neuromodulation incumbent competing for the same essential tremor patients.
- Boston Scientific: Boston Scientific's Vercise DBS system targets Parkinson's and essential tremor, and the company has expanded into peripheral nerve and sacral neuromodulation. Comparable as a broad incumbent in implantable neuromodulation with overlapping clinical indications.
- Electrocore: Electrocore manufactures non-invasive vagus nerve stimulation (nVNS) devices (gammaCore) for migraine, headache, and other neurological conditions. Comparable as a commercial-stage non-invasive neurostimulation company with overlapping regulatory and reimbursement profile (FDA-cleared, prescription DME).
Emerging players
- Helius Medical Technologies: Helius develops the Portable Neuromodulation Stimulator (PoNS), a non-invasive neurostimulation device for gait and balance disorders. Comparable as an early-stage, non-invasive neuromodulation wearable with overlapping regulatory pathway (FDA clearance) and similar commercial scale challenges.
- Synchron: Synchron is developing the Stentrode, an investigational brain-computer interface for paralyzed patients — closely comparable to Fasikl's MindForce NCI platform in target indication, regulatory pathway (FDA Breakthrough Device Designation), and end-user population (severe neurological impairment).
- Neuralink: Neuralink is developing implantable brain-computer interfaces for paralysis and neurological disorders. Comparable as an emerging competitor in the nerve-computer interface space with similar visionary positioning around AI-neural integration, though with a more invasive (intracranial) approach versus Fasikl's peripheral nerve approach.
- Blackrock Neurotech: Blackrock Neurotech is developing implantable brain-computer interfaces (Neuralace, NeuroPort) for paralysis and motor restoration. Comparable as a peer in the nerve-computer interface category targeting amputee and paralyzed patient populations Fasikl's MindForce addresses.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Fasikl social profiles
Digital presenceFasikl compliance and trust
Trust signalCompliance5 records
Fasikl financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fasikl leadership team
Management profileNumber of profiles
Profiles2 records
Fasikl subsidiaries and ownership
Company hierarchySubsidiaries1 record
Fasikl funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fasikl M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fasikl
What does Fasikl do?
Fasikl develops and sells AI-powered neurotechnology devices for treating neurological disorders. Its flagship product is the FDA-cleared Felix NeuroAI Wristband, a non-invasive, prescription-only wearable that delivers adaptive peripheral nerve stimulation guided by a cloud-based AI platform to provide all-day relief from essential tremor. The company also develops investigational nerve-computer interface systems (MindForce NCI, Epione, Fasikl-X) for prosthetic control and chronic post-amputation pain.
Is Fasikl a public or private company?
Fasikl is a private company. It is classified as venture growth investor backed and is currently operating.
When was Fasikl founded?
Fasikl was founded in 2019. It employs 11 to 50 people.
Where is Fasikl based?
Fasikl is headquartered in Bloomington, United States, in the North America region.
How does Fasikl make money?
Three revenue lines are on record. Felix NeuroAI Wristband Device Sales (Prescription DME) is the primary driver. The others are series B Venture Capital Investment and google Cloud Credits (Google for Startups Program).
Who are Fasikl's main competitors?
Direct peers on record are Cala Health and InSightec. Broad incumbents are Medtronic, Abbott, Boston Scientific and Electrocore. Emerging players are Helius Medical Technologies, Synchron, Neuralink and Blackrock Neurotech.
Does Fasikl have an API?
No public API is recorded for Fasikl.
What industry is Fasikl in?
Fasikl's product category is AI Neuromodulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.